Fredrik Frejd

CSO Affibody AB

Seminars

Tuesday 11th November 2025
HER2 Targeted Affibody Radioligand Therapy: Rationale & First in Human Design
1:30 pm
  • Translating mouse data to clinical doses
  • Considering novel imaging diagnostic versus histochemistry gold standard
  • Developing riskadjusted stepwise clinical development path
Fredrik Frejd, CSO Affibody A